Table 1.
Demographic and clinical comparison in 3 group of study
| Variables | Intervention Group; n (%) | Placebo Group; n (%) | P-value | ||
|---|---|---|---|---|---|
| Zolpidem | Amantadine | ||||
| Gender | Male | 15(68.2) | 15(68.2) | 15(68.2) | 1.000 |
| Female | 7(31.8) | 7(31.8) | 7(31.8) | ||
| Diabetes mellitus | Yes | 3(13.6) | 2(9.1) | 5(22.7) | 0.578 |
| No | 19(86.4) | 20(90.9) | 17(77.3) | ||
| Hypertension | Yes | 6(27.3) | 4(18.2) | 6(27.3) | 0.569 |
| No | 16(72.7) | 18(81.8) | 16(72.7) | ||
| Kidney disease | Yes | 1(4.5) | 1(4.5) | 0(0) | 1.000 |
| No | 21(95.5) | 21(95.5) | 22(100) | ||
| Hyperlipidemia | Yes | 3(13.6) | 2(9.1) | 1(4.5) | 0.864 |
| No | 19(86.4) | 20(90.9) | 21(95.5) | ||
| Thyroid disease | Yes | 0(0) | 0(0) | 0(0) | - |
| No | 22(100) | 22(100) | 22(100) | ||
| Smoking | Yes | 6(27.3) | 3(13.6) | 4(18.2) | 0.637 |
| No | 16(72.7) | 19(86.4) | 18(81.8) | ||
| Age (mean±SD) | 40.22±14.65 | 40.72±14.58 | 47.40±16.01 | 0.220 | |